Abrogation of lectin-like oxidized LDL receptor-1 attenuates acute myocardial ischemia-induced renal dysfunction by modulating systemic and local inflammation
- PMID: 22673889
- PMCID: PMC4045456
- DOI: 10.1038/ki.2012.186
Abrogation of lectin-like oxidized LDL receptor-1 attenuates acute myocardial ischemia-induced renal dysfunction by modulating systemic and local inflammation
Abstract
It is assumed that acute myocardial infarction affects renal function. To study the mechanism, we used mice following permanent ligation of their left coronary artery that results in extensive myocardial infarction. Soon after ligation, there was a marked rise in circulating pro-inflammatory cytokines and malondialdehyde (thiobarbituric acid-positive evidence of lipid peroxidation). Renal function had significantly declined by the third day in association with mild fibrosis, and swelling of glomeruli and tubules. There was a significant increase in the expression of the lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1), interelukin-1β, vascular cell adhesion molecule-1, and thiobarbituric acid-reactive substances in the kidney. Renal function showed some recovery by Day 21; however, there was progressive fibrosis of the kidneys. LOX-1 knockout mice had significantly diminished increases in systemic and renal pro-inflammatory cytokines, malondialdehyde, structural alterations, and decline in renal function than the wild-type mice following ligation of the left coronary artery. Cardiac function and survival rates were also significantly better in the LOX-1 knockout mice than in the wild-type mice. Hence, severe myocardial ischemia results in renal dysfunction and histological abnormalities suggestive of acute renal injury. Thus, LOX-1 is a key modulator among multiple mechanisms underlying renal dysfunction following extensive myocardial infarction.
Figures






Similar articles
-
LOX-1 abrogation reduces cardiac hypertrophy and collagen accumulation following chronic ischemia in the mouse.Gene Ther. 2012 May;19(5):522-31. doi: 10.1038/gt.2011.133. Epub 2011 Sep 22. Gene Ther. 2012. PMID: 21938018 Free PMC article.
-
LOX-1 abrogation reduces myocardial ischemia-reperfusion injury in mice.J Mol Cell Cardiol. 2008 Jan;44(1):76-83. doi: 10.1016/j.yjmcc.2007.10.009. Epub 2007 Oct 23. J Mol Cell Cardiol. 2008. PMID: 18022184
-
LOX-1 deletion alters signals of myocardial remodeling immediately after ischemia-reperfusion.Cardiovasc Res. 2007 Nov 1;76(2):292-302. doi: 10.1016/j.cardiores.2007.07.003. Epub 2007 Jul 18. Cardiovasc Res. 2007. PMID: 17707356
-
LOX-1: a critical player in the genesis and progression of myocardial ischemia.Cardiovasc Drugs Ther. 2011 Oct;25(5):431-40. doi: 10.1007/s10557-011-6329-1. Cardiovasc Drugs Ther. 2011. PMID: 21847544 Review.
-
LOX-1 in Atherosclerosis and Myocardial Ischemia: Biology, Genetics, and Modulation.J Am Coll Cardiol. 2017 Jun 6;69(22):2759-2768. doi: 10.1016/j.jacc.2017.04.010. J Am Coll Cardiol. 2017. PMID: 28571642 Review.
Cited by
-
Experimental coronary artery stenosis accelerates kidney damage in renovascular hypertensive swine.Kidney Int. 2015 Apr;87(4):719-27. doi: 10.1038/ki.2014.343. Epub 2014 Oct 22. Kidney Int. 2015. PMID: 25337776 Free PMC article.
-
Diet-induced increase in plasma oxidized LDL promotes early fibrosis in a renal porcine auto-transplantation model.J Transl Med. 2014 Mar 22;12:76. doi: 10.1186/1479-5876-12-76. J Transl Med. 2014. PMID: 24655356 Free PMC article.
-
Plasma proteome signatures of ASK1 inhibition by selonsertib associate with efficacy in the MOSAIC randomized trial for diabetic kidney disease.BMC Nephrol. 2025 May 15;26(1):244. doi: 10.1186/s12882-025-04166-4. BMC Nephrol. 2025. PMID: 40375085 Free PMC article. Clinical Trial.
-
Characterization of a murine model of cardiorenal syndrome type 1 by high-resolution Doppler sonography.J Ultrasound. 2014 Sep 20;18(3):229-35. doi: 10.1007/s40477-014-0129-y. eCollection 2015 Sep. J Ultrasound. 2014. PMID: 26261465 Free PMC article.
-
Toward Human Models of Cardiorenal Syndrome in vitro.Front Cardiovasc Med. 2022 May 26;9:889553. doi: 10.3389/fcvm.2022.889553. eCollection 2022. Front Cardiovasc Med. 2022. PMID: 35694669 Free PMC article. Review.
References
-
- Ronco C, Haapio M, House AA, et al. Cardiorenal syndrome. J Am Coll Cardiol. 2008;52:1527–1539. - PubMed
-
- Shlipak MG, Massie BM. The clinical challenge of cardiorenal syndrome. Circulation. 2004;110:1514–1517. - PubMed
-
- Gobal F, Deshmukh A, Shah S, et al. Triad of metabolic syndrome, chronic kidney disease, and coronary heart disease with a focus on microalbuminuria death by overeating. J Am Coll Cardiol. 2011;57:2303–2308. - PubMed
-
- van Kimmenade RR, Pinto Y, Januzzi JL., Jr When renal and cardiac insufficiencies intersect: is there a role for natriuretic peptide testing in the ‘cardio-renal syndrome’? Eur Heart J. 2007;28:2960–2961. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical